Document:

exv10w2

Execution Version

Exhibit 10.2

SEPARATION PAY AGREEMENT

     THIS SEPARATION PAY AGREEMENT (this “Agreement”), dated November 4, 2008, and effective as of
October 16, 2008, is between Zix Corporation, a Texas corporation (the “Company”), and Susan K.
Conner (“Employee”).

     WHEREAS, Employee is currently employed by the Company;

     WHEREAS, Employee is willing to continue working for the Company on an “at-will” basis;

     NOW, THEREFORE, in consideration of the foregoing and of the respective covenants and
agreements of the parties herein contained, the parties agree as follows:

1. Definitions.

     A. Acquiring Person. An “Acquiring Person” shall mean any person (including any
“person” as such term is used in Sections 13(d)(3) or 14(d)(2) of the Exchange Act that, together
with all Affiliates and Associates of such person, is the beneficial owner (as the term “beneficial
owner” is defined under Rule 13d-3 or any successor rule or regulation promulgated under the
Exchange Act)) of 10% or more of the outstanding Common Stock. The term “Acquiring Person” shall
not include the Company, any majority-owned subsidiary of the Company, any employee benefit plan of
the Company or a majority-owned subsidiary of the Company, or any person to the extent such person
is holding Common Stock for or pursuant to the terms of any such plan. For the purposes of this
Agreement, a person who becomes an Acquiring Person by acquiring beneficial ownership of 10% or
more of the Common Stock at any time after the date of this Agreement shall continue to be an
Acquiring Person whether or not such person continues to be the beneficial owner of 10% or more of
the outstanding Common Stock.

     B. Affiliate and Associate. “Affiliate” and “Associate” shall have the respective
meanings ascribed to such terms in Rule 12b-2 of the General Rules and Regulations under the
Exchange Act in effect on the date of this Agreement.

     C. Cause. “Cause” shall mean any of the following shall have occurred: (1) the
intentional and continued failure by Employee to substantially perform Employee’s employment
duties, such intentional action involving willful and deliberate malfeasance or gross negligence in
the performance of Employee’s duties (other than any such failure resulting from Employee’s
incapacity due to physical or mental illness), after written demand for substantial performance is
delivered by the Company’s Board of Directors (hereinafter, referred to as the “Board”) that
specifically identifies the manner in which the Board of Directors believes Employee has not
substantially performed Employee’s duties and that is not cured within five business days after
notice thereof by the Company to Employee; (2) the intentional engaging by Employee in misconduct
that is materially injurious to the Company; (3) the conviction of Employee or a plea of nolo
contendere, or the substantial equivalent to either of the foregoing, of or with respect to, any
felony;

 

 

(4) the commission of acts by Employee of moral turpitude that are injurious to the Company;
(5) a breach by Employee of the “confidentiality and invention” agreement between the Company and
Employee; (6) a breach by Employee of Employee’s obligations under this Agreement; or (7) a breach
by Employee of the Company’s “Code of Ethics for Senior Officers,” as currently in effect or
amended from time-to-time. For purposes of this definition, no act, or failure to act, on
Employee’s part shall be considered “intentional” unless done, or omitted to be done, by him not in
good faith and without reasonable belief that his action or omission was in, or not opposed to, the
best interest of the Company.

     Notwithstanding the foregoing, Employee shall not be deemed to have been terminated for Cause
without (1) reasonable written notice to Employee, setting forth the reasons for the Company’s
intention to terminate for Cause; (2) an opportunity for Employee to be heard before the Board (or
an authorized representative thereof); and (3) delivery to Employee of a written notice of
termination from the Board (or its authorized representative) finding that, in the good faith
opinion of the Board (or its authorized representative), Employee engaged in the conduct set forth
above in clause (1) or (2) of the preceding paragraph or an event specified in clause (3), (4),
(5), (6) or (7) of the preceding paragraph has occurred.

     D. Change in Control. A “Change in Control” of the Company shall have occurred if any
of the following events shall occur during the term of Employee’s employment:

     (1) The Company is merged, consolidated or reorganized into or with another
corporation or other legal person, other than an Affiliate, and as a result of such merger,
consolidation or reorganization, the Company or its shareholders or Affiliates immediately
before such transaction beneficially own, immediately after or as a result of such
transaction, equity securities of the surviving or acquiring corporation or such
corporation’s parent corporation possessing less than 51% of the voting power of the
surviving or acquiring person or such person’s parent corporation;

     (2) The Company sells all or substantially all of its assets to any other corporation
or other legal person, other than an Affiliate, and as a result of such sale, the Company
or its shareholders or Affiliates immediately before such transaction beneficially own,
immediately after or as a result of such transaction, equity securities of the surviving or
acquiring corporation or such corporation’s parent corporation possessing less than 51% of
the voting power of the surviving or acquiring person or such person’s parent corporation
(provided that this provision shall not apply to a registered public offering of securities
of a subsidiary of the Company, which offering is not part of a transaction otherwise a
part of or related to a Change in Control);

     (3) Any Acquiring Person has become the beneficial owner (as the term “beneficial
owner” is defined under Rule 13d-3 or any successor rule or regulation promulgated under
the Exchange Act) of securities which, when added

2

 

to any securities already owned by such person, would represent in the aggregate 35%
or more of the then outstanding securities of the Company which are entitled to vote to
elect any class of directors;

     (4) If, at any time, the Continuing Directors then serving on the Board cease for any
reason to constitute at least a majority thereof;

     (5) Any occurrence that would be required to be reported in response to Item 6(e) of
Schedule 14A of Regulation 14A or any successor rule or regulation promulgated under the
Exchange Act; or

     (6) Such other events that cause a Change in Control of the Company, as determined by
the Board in its sole discretion.

     E. Continuing Director. A “Continuing Director” shall mean a director of the Company
who (1) is not an Acquiring Person or an Affiliate or Associate thereof, or a representative of an
Acquiring Person or nominated for election by an Acquiring Person, and (2) was either (a) a member
of the Board on the date of this Agreement or (b) subsequently became a director of the Company and
whose initial election or initial nomination for election by the Company’s shareholders was
approved by a majority of the Continuing Directors then on the Board.

     F. Company. The “Company” shall mean Zix Corporation, a Texas corporation, or its
successors-in-interest, as the context requires.

     G. Exchange Act. “Exchange Act” shall mean the Securities Exchange Act of 1934, as
amended.

2. Termination Without Cause Payment. If the Company terminates Employee’s employment
other than for Cause, the Company shall pay to Employee an amount equal to nine (9) months
of Employee’s base salary, using Employee’s highest monthly base salary during the term of
Employee’s employment (the “Termination Without Cause Payment”), subject to receiving a release
reasonably satisfactory to the Company relating to employment matters.

3. Change In Control Payment. If Employee resigns from employment with the Company on or
before the 180th day following a Change in Control (with the day immediately following
the occurrence of the Change in Control being day “1”), the Company shall pay to Employee an amount
equal to nine (9) months of Employee’s base salary, using Employee’s highest monthly base salary
during the term of Employee’s employment (the “Change In Control Payment”), subject to receiving a
release reasonably satisfactory to the Company relating to employment matters.

4. Mode of Payment; Acceptance; No Overlapping Payments. The payments provided for in
Sections 2 and 3 shall, in the Company’s discretion, be paid either in nine (9) equal monthly cash
payments beginning within 30 days of the occurrence of the applicable event, or in a lump sum cash
payment paid within 30 days of the occurrence of the applicable

3

 

event. Regardless of the manner in which the applicable payment is made, the Employee shall be
responsible for all applicable withholdings for taxes and other withholdings required by applicable
law and any amounts owed by Employee to Company, and Employee shall pay the same to the Company
promptly upon demand if not otherwise withheld. The Company’s obligation to make the payments
provided for in Sections 2 and 3 is absolute, and such payments shall not be mitigated or offset by
virtue of Employee obtaining new employment or failing to seek new employment. Acceptance by
Employee of the Termination Without Cause Payment (Section 2) or Change In Control Payment (Section
3), as applicable, shall constitute a release by Employee of the Company and its affiliates,
shareholders, officers, employees, directors and other agents from all claims arising out of,
relating to, or in connection with, Employee’s employment with, or separation from employment with,
the Company and its Affiliates.

     Employee shall be entitled to receive pursuant to this Agreement only one of either (a) one
Termination Without Cause Payment (Section 2) or (b) one Change In Control Payment (Section 3),
i.e., not more than one of any of such payments is payable pursuant to this Agreement.

5. Conflict of Interest. Without limiting the Employee’s obligations to comply with the
Company’s Code of Conduct and Code of Ethics, Employee agrees that during the term of Employee’s
employment, Employee shall not:

     A. Engage, either directly or indirectly, in any activity which may involve a conflict of
interest with the Company or its Affiliates (a “Conflict of Interest”), including ownership in any
supplier, contractor, subcontractor, customer or other entity with which the Company does business
(other than as a shareholder of less than one percent (1%) of a publicly-traded or private class of
equity ownership); and

     B. Employee shall not accept any material payment, service, loan, gift, trip, entertainment or
other favor from a supplier, contractor, subcontractor, customer or other entity with which the
Company does business, and Employee shall promptly inform the Board as to each offer received by
Employee to engage in any such activity.

Employee agrees to disclose to the Company any other facts of which Employee becomes aware that
might involve or give rise to a Conflict of Interest or potential Conflict of Interest.

6. Non-competition. Beginning the date that Employee separates from employment with the
Company and through the nine (9) month anniversary of such separation from employment date,
Employee shall not:

     A. Directly or indirectly, compete with the Company’s Email Encryption business or
e-Prescribing business or any other material line of business being conducted by the Company
(“Other Material Business”), in each case, as the Email Encryption line of business, e-Prescribing
line of business, or Other Material Business line of business is comprised as of the date of the
Employee’s separation from employment. For purposes of this Agreement, “Competition” shall
include, without limitation, engaging, directly or

4

 

indirectly, in any business, whether as proprietor, partner, joint venturer, employee, agent,
officer, director, consultant, advisor, or holder of more than one percent (1%) of any publicly
traded or private class of equity ownership of a business enterprise, that is competitive with the
Company’s Email Encryption business or e-Prescribing business or Other Material Business;

     B. Directly or indirectly, solicit to do, or do, competing business with (i) any person that
is a customer of the Company’s Email Encryption business or e-Prescribing business or Other
Material Business as of the date of the Employee’s separation from employment, or (ii) any person
that has been a customer of the Company’s Email Encryption business or e-Prescribing business or
Other Material Business within the six months preceding such date; or

     C. Directly or indirectly, solicit to hire, or hire, any person that is an employee of the
Company (including its affiliated companies) as of the date of the Employee’s separation from
employment, or was an employee within the 3 month period preceding such date, except by way of
bona-fide general advertising.

     Although the Company and Employee have, in good faith, used their best efforts to make the
covenants of this Section reasonable in all pertinent respects, and it is not anticipated, nor is
it intended, by either party to this Agreement that any arbitrator or court will find it necessary
to reform any of such covenants to make it reasonable in all pertinent respects, the Company and
Employee understand and agree that if an arbitrator or court determines it necessary to reform any
of such covenants to make it reasonable in all pertinent respects, damages, if any, for a breach
of the non-competition covenant, as so reformed, shall be deemed to accrue to the Company as and
from the date of such a breach only and so far as the damages for such breach related to an action
that accrued within the scope of the covenant as so reformed.

7. Miscellaneous.

     A. Pending Litigation; Indemnification. During Employee’s employment and following
Employee’s separation from employment, with respect to any lawsuits currently pending or hereafter
asserted against the Company that pertain to (i) matters reasonably within the purview of
Employee’s job responsibilities while employed with the Company or (ii) matters for which the
Employee has particular knowledge, Employee agrees to cooperate reasonably in the defense of the
litigation thereof, including signing affidavits and making himself or herself available for
interviews, deposition preparation, deposition, and trial. If Employee is requested to assist
with litigation activities following Employee’s separation from employment other than those
litigation activities in which Employee would be required to participate as a named party, the
Company agrees to pay all reasonable documented out-of-pocket costs and lost income up to a maximum
of $1,000 per day incurred in connection with such activities. Without the Company’s prior consent,
Employee agrees not to comment publicly on any such litigation or any of the issues in the
litigation. Without the Company’s prior consent, Employee also agrees not to discuss any such
litigation, or cooperate, with the plaintiffs, their attorneys, or their representatives. The
Company acknowledges that the Employee

5

 

has certain rights to indemnification as an officer of the Company as set forth in the
Company’s Restated Bylaws if the Employee is named as a party in litigation.

     B. Waiver. No waiver of any provision of this Agreement shall be deemed, or shall
constitute, a waiver of any other provision, whether or not similar, nor shall any waiver
constitute a waiver of any continuing or succeeding breach of such provision, a waiver of the
provision itself, or a waiver of any right under this Agreement. No waiver shall be binding unless
executed in writing by the party making the waiver.

     C. Limitation of Rights. Nothing in this Agreement, except as specifically stated in
this Agreement, is intended to confer any rights or remedies under or by reason of this Agreement
on any persons other than the parties to it and their respective permitted successors and assigns
and other legal representatives.

     D. Remedies. Employee hereby agrees that a violation of the provisions of Section 5,
Section 6, or Section 7.A. would cause irreparable injury to the Company for which it would have no
adequate remedy at law. Accordingly, in the event of any such violation, the Company shall be
entitled to preliminary and other injunctive relief. Any such injunctive relief shall be in
addition to any other remedies to which the Company may be entitled at law or in equity, or
otherwise.

     E. Notice. Any consent, notice, demand, or other communication regarding any payment
required or permitted hereby must be in writing to be effective and shall be deemed to have been
received on the date delivered, if personally delivered, or the date received, if delivered
otherwise, addressed to the applicable party at the address for such party set forth below or at
such other address as such party may designate by like notice:

The Company:

Zix Corporation

2711 North Haskell Avenue

Suite 2200, LB 36

Dallas, Texas 75204-2960, Attn: General Counsel

If to Employee, to the address on file in the Company’s records.

     F. Entirety and Amendments. This Agreement embodies the entire agreement between the
parties with respect to the subject matter hereof and supersedes all prior agreements and
understandings relating to the subject matter hereof. This Agreement is the separation pay
agreement referred to in that certain employment offer letter addressed to Employee, dated October
6, 2008.

     G. Successors and Assigns. This Agreement will be binding upon and inure to the
benefit of the parties to this Agreement and any successors-in-interest to the Company, but
otherwise, neither this Agreement nor any rights or obligations under this Agreement may be
assigned by Employee.

6

 

     H. Governing Law. This Agreement shall be governed by and construed and enforced in
accordance with the laws of the State of Texas (excluding its conflict of laws rules) and
applicable federal law.

     I. Cumulative Remedies. No remedy in this Agreement conferred upon any party is
intended to be exclusive of any other benefit or remedy, and each and every such remedy shall be
cumulative and shall be in addition to every other benefit or remedy given under this Agreement or
now or hereafter existing at law or in equity or by statute or otherwise. No single or partial
exercise by any party of any right, power, or remedy under this Agreement shall preclude any other
or further exercise thereof.

     J. Multiple Counterparts. This Agreement may be executed in a number of identical
counterparts, each of which constitute collectively, one agreement; but in making proof of this
Agreement, it shall not be necessary to produce or account for more than one counterpart.

     K. Descriptive Headings. The headings, captions, and arrangements used in this
Agreement are for convenience only and shall not be deemed to limit, amplify, or modify the terms
of this Agreement, nor affect the meaning hereof.

     L. Arbitration. The Company and the Employee acknowledge that they have executed that
certain mutual alternate dispute resolution agreement, dated October 24, 2008 (the “Arbitration
Agreement”). The Company and the Employee agree that, except as otherwise provided in the
Arbitration Agreement, all claims, demands, causes of action, disputes, controversies, or other
matters in question (“Claims”), whether sounding in contract, tort, or otherwise and whether
provided by statute or common law, arising under this Agreement or the Employee’s employment (or
its termination) are governed by the Arbitration Agreement.

     IN WITNESS WHEREOF, the parties have executed this Agreement effective on the date and year
first above written.

	 	 	 	 	 
	 	ZIX CORPORATION

 	 
	 	By:  	     /s/ Richard D. Spurr
 	 
	 	 	Richard D. Spurr 	 
	 	 	Chairman & Chief Executive Officer 	 
	 
	 	EMPLOYEE

 	 
	 	 	     /s/ Susan K. Conner
 	 
	 	 	Susan K. Conner 	 
	 	 	 
	 

7exv10w1

Exhibit 10.1

EXECUTION VERSION

AMENDMENT NO. 1 TO SECOND AMENDED

AND RESTATED CREDIT AGREEMENT

     This AMENDMENT NO. 1 TO SECOND AMENDED AND RESTATED CREDIT AGREEMENT (this
“Amendment”) is dated as of November 7, 2008 (the “Execution Date”), and is by and
among GENERAL ELECTRIC CAPITAL CORPORATION, a Delaware corporation, individually as Lender and as
Agent for the Lenders (“Agent”), the other Lenders signatory hereto (each a
“Lender” and collectively, the “Lenders”), ODYSSEY HEALTHCARE OPERATING A, LP, a
Delaware limited partnership (“OpCoA”), ODYSSEY HEALTHCARE OPERATING B, LP, a Delaware
limited partnership (“OpCoB”), HOSPICE OF THE PALM COAST, INC., a Florida not for profit
corporation (“Palm Coast”), and VISTACARE, INC., a Delaware corporation
(“VistaCare”; OpCoA, OpCoB, Palm Coast and VistaCare being referred to together as the
“Borrowers” and each individually as a “Borrower”).

WITNESSETH:

     WHEREAS, pursuant to that certain Second Amended and Restated Credit Agreement dated as of
February 28, 2008, by and among Agent, the other Lenders signatory thereto from time to time, the
Borrowers and the other Credit Parties signatory thereto (as amended or otherwise modified from
time to time, the “Credit Agreement”; capitalized terms used herein and not otherwise
defined herein shall have the meaning ascribed to such terms in the Credit Agreement), Agent and
Lenders agreed, subject to the terms and provisions thereof, to provide certain loans and other
financial accommodations to the Borrowers; and

     WHEREAS, the Borrowers desire that Agent and Lenders amend the Credit Agreement in certain
respects, as more fully set forth herein, and Agent and Lenders are agreeable to such request.

     NOW, THEREFORE, in consideration of the premises and other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

     1. Amendments to Credit Agreement. Subject to the satisfaction of the conditions set
forth in Section 2 below, and in reliance on the representations and warranties set forth
in Section 4 below, the Credit Agreement is amended as follows:

     (a) Clause (c) of Section 6.2 of the Credit Agreement is hereby amended by deleting the
reference to “(the investments described in clauses (i) — (v) below and the
investments permitted in clause (d) below are collectively referred to as “Cash
Equivalents”)” and replacing it with the following:

“(the investments described in clauses (i) — (v) below are
collectively referred to as “Cash Equivalents”)”; and

     (b) Clause (d) of Section 6.2 of the Credit Agreement is hereby amended and restated and
replaced with the following:

 

 

“(d) the Credit Parties may hold investments comprised of auction rate securities
disclosed to Agent in writing in an aggregate amount not exceeding $17,100,000, but
only to the extent such investments were made prior to, and existed as of, the
Closing Date, and”.

     2. Consent to Assignment of Trademarks. The Borrowers have informed Agent and the
Lenders that VistaCare desires to sell, transfer, convey, assign and deliver to Odyssey HealthCare,
Inc., a Delaware corporation (“Holdings”), subject to the security interests granted under
the Collateral Documents, certain United States trademark registrations listed on Schedule
I attached hereto owned by VistaCare, pursuant to that certain Trademark Assignment to be dated
on or after the date hereof between Holdings and VistaCare. In reliance on the representations and
warranties set forth in this Amendment, Agent and the Requisite Lenders hereby consent to such
assignment subject to the terms and conditions contained herein. The foregoing consent is a
limited consent, which shall be effective only with respect to the specific facts set forth above.
Such limited consent shall not be deemed to constitute a consent or waiver of any other term,
provision or condition of the Credit Agreement or to prejudice any right or remedy that Agent or
Lenders may now have or may have in the future under or in connection with any of the Loan
Documents.

     3. Conditions. The effectiveness of this Amendment is expressly conditioned upon
Agent’s receipt (on behalf of itself and each of Lenders) from the Borrowers of the following, all
of which shall be in form and substance satisfactory to Agent:

     (a) This Amendment duly executed by each of the Borrowers and the Requisite Lenders;

     (b) Payment by the Borrowers to Agent, for the account of each consenting Lender that has
executed a signature page to this Amendment and delivered the same to Agent on or before 5:00 p.m.
(New York time) on November 7, 2008, of an amendment fee in immediately available funds in an
amount equal to $7,500.00 per consenting Lender, which fee is deemed fully earned and
non-refundable on payment thereof to Agent; and

     (c) Such other documents, instruments and agreements as Agent may reasonably request.

     4. Reference to and Effect on the Credit Agreement.

     (a) Upon the effectiveness of this Amendment, each reference in the Credit Agreement to “this
Agreement,” “hereunder,” “hereof,” “herein” or words of like import and each reference to the
Credit Agreement in each Loan Document shall mean and be a reference to the Credit Agreement, as
amended hereby.

     (b) Except as specifically amended above, all of the terms, conditions and covenants of the
Credit Agreement and the other Loan Documents shall remain unaltered and in full force and effect
and shall be binding upon each of the Borrowers and the other Credit Parties in all respects and
are hereby ratified and confirmed.

 

 

     (c) Except as specifically set forth above, the execution, delivery and effectiveness of this
Amendment shall not operate as a waiver of (a) any right, power or remedy of any Lender or Agent
under the Credit Agreement or any of the Loan Documents, or (b) any Event of Default or Default
under the Credit Agreement.

     (d) This Amendment shall constitute a Loan Document.

     5. Representations and Warranties. To induce Agent and the Lenders to enter into this
Amendment, each Borrower hereby represents and warrants to Agent and the Lenders that:

     (a) Representations and Warranties. (i) No Default or Event of Default has occurred
or is continuing and (ii) no representation or warranty of any Credit Party contained in the Credit
Agreement or any of the other Loan Documents, including this Amendment, is untrue or incorrect in
any material respect as of the date hereof, except to the extent that such representation or
warranty expressly relates to an earlier date, in which case it shall be true and correct as of
such earlier date.

     (b) Power, Authorization, Enforceable Obligations. The execution, delivery and
performance by each Borrower of this Amendment: (a) are within such Borrower’s power; (b) have
been duly authorized by all necessary corporate, limited liability company or limited partnership
action; (c) do not contravene any provision of such Borrower’s charter, bylaws or partnership or
operating agreement as applicable; (d) do not violate any law or regulation, or any order or decree
of any court or Governmental Authority; (e) do not conflict with or result in the breach or
termination of, constitute a default under or accelerate or permit the acceleration of any
performance required by, any indenture, mortgage, deed of trust, lease, agreement or other
instrument to which such Person is a party or by which such Person or any of its property is bound;
(f) do not result in the creation or imposition of any Lien upon any of the property of such Person
other than those in favor of Agent, on behalf of itself and Lenders, pursuant to the Loan
Documents; and (g) do not require the consent or approval of any Governmental Authority or any
other Person. This Amendment has been duly executed and delivered by each Borrower and constitutes
a legal, valid and binding obligation of each Borrower enforceable against it in accordance with
its terms, subject to applicable bankruptcy, insolvency, reorganization, moratorium or other laws
affecting creditors’ rights generally and subject to general principles of equity regardless of
whether considered in a proceeding in law or equity.

     6. Costs and Expenses. The Borrowers agree to pay on demand all reasonable costs and
expenses of Agent in connection with the preparation, execution and delivery of this Amendment,
including the reasonable fees and out-of-pocket expenses of counsel for Agent with respect thereto.

     7. Execution in Counterparts. This Amendment may be executed in any number of
counterparts and by different parties hereto in separate counterparts, each of which when so
executed shall be deemed to be an original and all of which taken together shall constitute one and
the same agreement.

 

 

     8. Headings. Section headings in this Amendment are included herein for convenience
of reference only and shall not constitute a part of this Amendment for any other purposes.

     9. Severability. Wherever possible, each provision of this Amendment shall be
interpreted in such a manner as to be effective and valid under applicable law, but if any
provision of this Amendment shall be prohibited by or invalid under applicable law, such provision
shall be ineffective to the extent of such prohibition or invalidity, without invalidating the
remainder of such provision or the remaining provisions of this Amendment.

     10. Incorporation of Credit Agreement. The provisions contained in Sections 11.9 and
11.13 of the Credit Agreement are incorporated herein by reference to the same extent as if
reproduced herein in their entirety.

[Signature Pages Follow]

 

 

     IN WITNESS WHEREOF, this Amendment has been executed as of the day and year first written
above.

	 	 	 	 	 	 	 	 	 
	 	 	BORROWERS:	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	ODYSSEY HEALTHCARE OPERATING A, LP	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	By:	 	Odyssey HealthCare GP, LLC	 	 
	 	 	Its:	 	General Partner	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	 	 	By:

Name:
	 	/s/ R. Dirk Allison
 

R. Dirk Allison
	 	 
	 

	 	 	 	Title:
	 	Senior Vice President and Chief Financial Officer	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	ODYSSEY HEALTHCARE OPERATING B, LP	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	By:	 	Odyssey HealthCare GP, LLC	 	 
	 	 	Its:	 	General Partner	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	 	 	By:

Name:
	 	/s/ R. Dirk Allison
 

R. Dirk Allison
	 	 
	 

	 	 	 	Title:
	 	Senior Vice President and Chief Financial Officer	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	HOSPICE OF THE PALM COAST, INC.	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	 	 	By:

Name:
	 	/s/ R. Dirk Allison
 

R. Dirk Allison
	 	 
	 

	 	 	 	Title:
	 	Senior Vice President and Chief Financial Officer	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	VISTACARE, INC.	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	 	 	By:

Name:
	 	/s/ R. Dirk Allison
 

R. Dirk Allison
	 	 
	 

	 	 	 	Title:
	 	Senior Vice President and Chief Financial Officer	 	 

Signature Page to Amendment No. 1

 

 

	 	 	 	 	 	 	 
	 	 	AGENT AND LENDERS:	 	 
	 
	 	 	 	 	 	 
	 	 	GENERAL ELECTRIC CAPITAL CORPORATION, as Agent and
Lender	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	/s/ John Dale	 	 
	 

	 	Name:
	 	John Dale

	 	 
	 

	 	Title:
	 	Duly Authorized Signatory	 	 

Signature Page to Amendment No. 1

 

 

	 	 	 	 	 	 	 
	 	 	BANK OF TEXAS, NA, as a Lender	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	/s/ Bianca A. Gulberti	 	 
	 

	 	Name:
	 	 

Bianca
A. Gulberti	 	 
	 

	 	Title:
	 	 
Vice
President
	 	 
	 

	 	 	 	 

	 	 

Signature Page to Amendment No. 1

 

 

	 	 	 	 	 	 	 
	 	 	BANK OF AMERICA, N.A., as a Lender	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	/s/ Daniel Penkar	 	 
	 

	 	Name:
	 	 
Daniel
Penkar
	 	 
	 

	 	Title:
	 	 
Senior
Vice President
	 	 
	 

	 	 	 	 

	 	 

Signature Page to Amendment No. 1

 

 

	 	 	 	 	 	 	 
	 	 	COMPASS BANK, as a Lender	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	/s/
Key Coker 	 	 
	 

	 	Name:	 	Key Coker 	 	 
	 

	 	Title:
	 	Executive
Vice President 
	 	 

Signature Page to Amendment No. 1

 

 

	 	 	 	 	 	 	 
	 	 	FIFTH THIRD BANK, as a Lender	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	/s/ Eva Szuen McQuillen 	 	 
	 

	 	Name:
	 	Eva Szuen McQuillen 
	 	 
	 

	 	Title:
	 	Bank
Officer 
	 	 

Signature Page to Amendment No. 1

 

 

	 	 	 	 	 	 	 
	 	 	SUNTRUST BANK, as a Lender	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	/s/ Helen C. Hartz 	 	 
	 

	 	Name:
	 	Helen C. Hartz 
	 	 
	 

	 	Title:
	 	Vice
President 
	 	 

Signature Page to Amendment No. 1

 

 

	 	 	 	 	 	 	 
	 	 	UNION BANK OF CALIFORNIA, N.A., as a Lender	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	/s/ Richard A. Lopatt	 	 
	 

	 	Name:
	 	Richard
A. Lopatt

	 	 
	 

	 	Title:
	 	Vice
President

	 	 
	 

	 	 	 	 

	 	 

Signature Page to Amendment No. 1

 

 

	 	 	 	 	 	 	 
	 	 	WELLS FARGO FOOTHILL, LLC, as a Lender	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	/s/ Peter Freyer	 	 
	 

	 	Name:
	 	Peter Freyer

	 	 
	 

	 	Title:
	 	Vice
President

	 	 
	 

	 	 	 	 

	 	 

Signature Page to Amendment No. 1

 

 

SCHEDULE I

TRADEMARK REGISTRATIONS

	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	Registration Number /	 	 
	Title
	 	Status	 	Application Number	 	Registration Date
	Excellence Without Exception
	 	Registered	 	 	2,977,864	 	 	 	7/26/05	 
	VistaCare
	 	Registered	 	 	2,672,152	 	 	 	1/7/03	 
	VistaCare
Excellence Without Exception
	 	Registered	 	 	3,310,236	 	 	 	10/16/07

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00149-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00149-of-00352.parquet"}]]